(±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats
- 1 July 1989
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 102 (2-3) , 325-331
- https://doi.org/10.1016/0304-3940(89)90100-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Dual synaptic effects of activating M1-muscarinic receptors, in superior cervical ganglia of rabbitsBrain Research, 1988
- Time course of ethylcholine aziridinium ion (AF64A)-induced cholinotoxicity in vivoNeuropharmacology, 1987
- Binding studies with [3H]cis-methyldioxolane in different tissuesNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1987
- Potential Animal Models for Senile Dementia of Alzheimer's Type, with Emphasis on AF64A-Induced CholinotoxicityAnnual Review of Pharmacology and Toxicology, 1986
- Loss of M2 Muscarine Receptors in the Cerebral Cortex in Alzheimer's Disease and Experimental Cholinergic DenervationScience, 1985
- Central administration of the muscarinic receptor subtype - selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouseJournal of Pharmacy and Pharmacology, 1983
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Pirenzepine distinguishes between different subclasses of muscarinic receptorsNature, 1980
- A new probe for heterogeneity in muscarinic receptors: 2-methyl-spiro-(1,3-dioxolane-4,3′)-quinuclidineEuropean Journal of Pharmacology, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973